btste of @ennegnee
PUBLIC CHAPTER NO. 1O4O
HOUSE BILL NO. 1832
By Representatives Hawk, Casada, Dunn, Madam Speaker Harulell, Kumar, Love, Favors, Johnson, Hardaway, Terry, Thompson, Akbari, Gamper, Mark White, Staples, Powers
Substituted for: Senate Bill No. 2258
By Senators Norris, Yager, Haile
AN ACT to amend Tennessee Code Annotated, Title 39, Chapter 17, Part 4; Tille 41, Chapter 21, Par12; Title 53 and Title 63, relative to controlled or addictive substances.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE
SECTION 1. Tennessee Code Annotated, Section 39-17-403(9), is amended by deleting the subsection in its entirety and substituting the following:
(g) The commissioner of mental health and substance abuse services, upon the agreement of the commissioner of health, in cooperation with the board of pharmacy, and in consultation with the director of the Tennessee bureau of investigation, shall revise and republish the schedules annually.
SECTION 2. Tennessee Code Annotated, Section 39-17-404, is amended by deleting the section in its entirety and substituting the following:
(a) The controlled substances listed or to be listed in the schedules in this part are included by whatever official, common, usual, chemical, or trade name designated.
(b) Notwithstanding any law to the contrary, the following are excluded from all schedules:
(1) Non-narcotic substances excluded under 21 CFR 1308.22, as amended;
(2) Chemical preparations exempted under 21 CFR 1308.24, as amended;
(3) Veterinary anabolic steroid implant products excluded under 21 CFR 1308.26, as amended;
(4) Prescription products exempted under 21 CFR 1308.32, as amended;
(5) Anabolic steroid products exempted under 21 CFR 1308.34, as amended; and
(6) Certain cannabis plant material, and products made from such material, that contain tetrahydrocannabinols and that are exempted under 21 CFR 1308.35, as amended.
SECTION 3. Tennessee Code Annotated, Section 39-17-406, is amended by deleting the section in its entirety and substituting the following:
(a) Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.
(b) Opiates, unless specifically excepted or unless listed in another schedule, means any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation; provided, that for HB {832
the purposes of subdivision (bX4SXBXxv), 3-Methylfentanyl, only, "isomer" includes the optical and geometric isomers:
(1) Acetylmethadol;
(2) Allylprodine;
(3) Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol; levomethadyl acetate; or LAAM);
(4) Alphameprodine;
(5) Alphamethadol;
(6) Benzethidine;
(7) Betacetylmethadol ;
(8) Betameprodine;
(9) Betamethadol;
(10) Betaprodine;
(11) Clonitazene;
(12) Dextromoramide;
(13) Diampromide;
(1 4) Diethylthiambutene;
(15) Difenoxin;
(16) Dimenoxadol;
(17) Dimepheptanol;
(1 8) Dimethylthiambutene;
(1 9) Dioxaphetyl butyrate;
(20) Dipipanone;
(21 ) Ethylmethylthiambutene;
(22) Etonitazene;
(23) Etoxeridine;
(24) Furethidine;
(25) Hydroxypethidine;
(26) Ketobemidone;
(27) Levomoramide;
(28) Levophenacylmorphan ;
(29) Morpheridine;
( (30) MPPP 1 -methyl-4-phenyl-4-propionoxypiperidine) ;
(31) Noracymethadol;
2 HB 1832
(32) Norlevorphanol;
(33) Normethadone;
(34) Norpipanone;
(35) PEPAP ( 1 -(2-phenylethyl)-4-phenyl-4-acetorypiperidine) ;
(36) Phenadoxone;
(37) Phenampromide;
(38) Phenomorphan;
(39) Phenoperidine;
(40) Piritramide;
(41) Proheptazine;
(42) Properidine;
(43) Propiram;
(44) Racemoramide;
(45) Tilidine;
(46) Trimeperidine;
(47) U47700; or
(48) Fentanyl derivatives and analogues:
(A) Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United states food and drug administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a 4-anilidopiperidine structure:
(i) With or without substitution at the carbonyl of the aniline moiety with alkyl, alkenyl, carboalkoxy, cycloalkyl, methoxyalkyl, cyanoalkyl, or aryl groups, or furanyl, dihydrofuranyl, benzyl moiety, or rings containing heteroatoms sulfur, oxygen, or nitrogen;
(ii) With or without substitution at the piperidine amino moiety with a phenethyl, benzyl, alkylaryl (including heteroaromatics), alkyltetrazolyl ring, or an alkyl or carbomethoxy group, whether or not further substituted in the ring or group;
(iii) With or without substitution or addition to the piperdine ring to any extent with one or more methyl, carbomethoxy, methoxy, methoxymethyl, aryl, allyl, or ester groups;
(iv) With or without substitution of one or more hydrogen atoms for halogens, or methyl, alkyl, or methoxy groups, in the aromatic ring of the anilide moiety;
(v) With or without substitution at the alpha or beta position of the piperidine ring with alkyl, hydroxyl, or methoxy groups;
3 HB 1832
(vi) With or without substitution of the benzene ring of the anilide moiety for an aromatic heterocycle; or
(vii) With or without substitution of the piperidine ring for a pyrrolidine ring, perhydroazepine ring, or azepine ring; and
(B) The application of subdivision (b)(48)(A) includes, but is not limited to, any of the following:
(i) Acetylfentanyl (N-(1 -phenethylpiperidin-4-yl)-N- phenylacetamide);
(ii) Acetyl-alpha-methylfentanyl (N-[1 -(1 -methyl-2- phenethyl)-4-piperidnyll-N-phenyl-acetamide);
(iii) Acryl fentanyl (N-( 1 -phenethylpiperidin-4-yl)-N- phenylacrylamide);
(iv) Alpha-methylfentanyl (N-[ 1 -(alpha-methyl-beta- phenyl)ethyl-4-piperidyllpropionanilide; 1 -( 1 -methyl-2-phenylethyl)-
4-(N-propanilido)piperidine) ;
(v) Alpha-methylthiofentanyl (N-[1 -methyl-2-(2-
thienyl)ethyl-4-piperidinyll-N-phenylpropanamide) ;
(vi) Benzodioxolefentanyl ;
(vii) Beta-hydroxyfentanyl (N-[1 -(2-hydroxy-2-phenethyl)-4-
piperidinyll-N-phenylpropanam ide) ;
(viii) Beta-hydroxythiofentanyl (N-[1 -[2-hydroxy-2- (thiophen-2-yl)ethyllpiperidin-4-yll-N-phenylpropionamide) ; N-[ 1 - [2-hyd roxy-2-(2{h ienyl)ethyl]-4-pi perid i nyll-N- phenylpropanamide);
(ix) Beta-hydroxy-3-methylfentanyl (N-[1 -(2-hydroxy-2-
phenethyl)-3-methyl-4-piperidinyll-N-phenylpropanamide) ;
(x) Butyrylfentanyl (N-( 1 -phenethylpiperidin-4-yl)-N- phenylbutyram ide; N-(1 -phenethylpiperidin-4-yl)-N- phenylbutanamide);
(xi) Cyclopentyl fentanyl;
(xii) lsobutyryl fentanyl;
(xiii) Furanyl fentanyl;
(xiv) Lofentanil;
(xv) 3-Methylfentanyl (N-[3-methyl-1 -(2-phenylethyl)-4-
piperidyll-N-phenylpropanamide) ;
(xvi) 3-Methylthiofentanyl (N-[3-methyl-1 -(2thienyl)ethyt-4-
piperidinyll-N-phenylpropanam ide) ;
(xvii) Ocfentanil;
(xviii) Ohmefentanyl;
(xix) Para-fluorofentanyl (N-(a-fl uorophenyt)-N-[ 1 -(2- phenethyl)-4-piperidinyll propanamide);
(n) Pa ra-fl uoroisobutyryl fentanyl (N -(4-f tuorophenyl)-N-( 1 - phenethylpiperidin-4-yl)isobutyramide; 4-fluoroisobutyryl fentanyl ;
4 HB 1832
(xxi) Pentanoyl fentanyl;
(xxii) Thiofentanyl; or
(>xiii) Valeryl fentanyl.
(c) Opium derivatives, unless specifically excepted or unless listed in another schedule, means any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dihydromorphine;
(9) Drotebanol;
(10) Etorphine (except hydrochloride salt);
(11) Heroin;
(12) Hydromorphinol;
(1 3) Methyldesorphine;
(1 4) Methyldihydromorphine;
(1 5) Morphine methylbromide;
(1 6) Morphine methylsulfonate;
(1 7) Morphine-N-Oxide;
(18) Myrophine;
(19) Nicocodeine;
(20) Nicomorphine;
(21) Normorphine;
(22) Pholcodine; or
(23) Thebacon.
(d) Hallucinogenic substances, unless specifically excepted or unless listed in another schedule, means any material, compound mixture, or preparation that contains any quantity of the following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specified chemical designation; provided, that for purposes of this subsection (d) only, "isomer" includes the optical, positional, and geometric isomers:
5 HB 1832
(1 ) Alpha-ethyltryptam ine
Other names: etryptamine; Monase; [alpha]-ethyl-1H-indole-3-ethanamine; 3-(2- aminobutyl) indole; lalphal-ET; and AET; ET; Trip;
(2) Alpha-methyltryptamine
Other name: AMT;
(3) 4-Bromo-2, 5-dimethoxyam phetamine
Other names: 4-Bromo-2,5-dimethoxy-[alpha]-methylphenethylamine; 4-bromo- 2,5-DMA;
(4) 4-Bromo-2, 5-dimethoxyphenethylamine
Other names: 2-(4-Bromo-2, 5-dimethoxyphenyl)- 1 -aminoethane; alpha- desmethyl DOB; 2C-B; Nexus;
(Q 2-@-Brom o-2, 5-d imethoxyphenyl)-N-(2-methoxybenzyt)ethana m i ne
Other names: 25B-NBOMe; 2C-B-NBOMe; 258; Cimbi-36;
(6) Bufotenine
Other names: 3-([beta]-Dimethylaminoethyl)-S-hydroxyindole; 3-(2 dimethylam inoethyl)-5-indolol ; N, N-dimethylserotonin ; S-hydroxy-N, N- dimethyltryptamine; mappine;
(7 ) 2- (4-Chloro-2, 5-dimethoryphenyl)-N-(2-methoxybenzyl)ethanam ine
Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82;
(8) Diethyltryptamine
Other names: N,N-Diethyltryptamine; DET;
(9) 2, 5-Dimethoxyamphetamine
Other names: 2,5-Dimethoxy-[alpha]-methylphenethylamine; 2,5-DMA;
( 1 0) 2, 5-Dimethoxy-4-ethylamphetamine
Other name: DOET;
(1 1) 2,5 D i m eth oxy-4- ( n)-p ro pylth i o p h e n ethyl a m i ne
Other name: 2C-f-7;
(1 2) Dimethyltryptamine
Other name: DMT;
(13) Ethylamine analogue of phencyclidine
Other names: N-Ethyl-1 -phenylcyclohexylamine; (1 -phenylcyclohexyl)ethylamine; N-(1 -phenylcyclohexyl)ethylamine; cyclohexamine; PCE;
(14) lbogaine
Other names: 7-Ethyl-6,6[beta],7,8,9 ,10,12,13-octahydro-2-methoxy-6,9- methano-5H-pyrido 11',2' :1,2lazepino[S,4-b]indole; Tabenanthe iboga;
(1 5) 2-(4-iod o-2, 5-di methoxyphenyl)-N-(2-methoxybenzyt)ethana m i ne
6 HB 1832
Other names: 251-NBOMe; 2C-l-NBOMe; 251; Cimbi-S;
(16) Lysergic acid diethylamide
Other name: LSD;
(17) Mescaline
Other name: Constituent of "Peyote" cacti;
(1 8) a-Methoxyamphetamine
Other names: 4-methoxy-[alpha]-methylphenethylam ine; paramethoxyamphetam ine; PMA;
(1 9) S-Methoxy-3,4-methylenedioxyam phetamine;
(20) 5-Methoxy-N, N-diisopropyltryptam ine
Other name: S-MeO-DIPT;
(21 ) 5-methoxy-N, N-dimethyltryptamine
Other names: 5-methoxy-3-[2-(dimethylam ino)ethyl]indole; 5-MeO-DMT;
(22) a-Methyl-2, 5-dimethoxyam phetamine
Other names: 4-methyl-2, 5-dimethoxy-[alpha]-methylphenethylam ine; DOM ; STP;
(23) 3,4-Methylenedioxyamphetam ine;
(24) 3,4-Methylenedioxymetham phetamine
Other name: MDMA;
(25) 3,4-Methylened ioxy-N-ethylam phetamine
Other names: N-ethyl-alpha-methyl 3,4(methylenedioxy) phenethylamine; N-ethyl MDA; MDE; MDEA;
(26) 3,4-Methylenedioxy-N-methylcathinone
Other name: Methylone;
(27) N-Ethyl-3-piperidyl benzilate;
(28) N-Hydroxy-3,4-methylenedioxyamphetamine
Other names: N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine; N- hydroxy MDA;
(29) N-methyl-3-piperidyl benzilate;
(30) Parahexyl
Other names: 3-Heryl-1 -hydroxy-7,8,9, 1 O-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran; Synhexyl;
(31) Peyote
Meaning all parts of the plant presently classified botanically as Lophophora williamsii Lamaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative,
7 HB 1832
mixture, or preparation of such plant or its seeds or extracts (lnterprets 21 U.S.C. $ 812(c), Schedule l(cX12));
(32) Psilocybin (constituent of magic mushrooms);
(33) Psilocyn (constituent of magic mushrooms);
(34) Pyrrolidine analogue of phencyclidine (1 -(1 -phenylcyclohexyl)- pyrrolidine)
Other names: PCPy; PHP;
(35) 1 -[ 1 -(2-Thienyl)cyclohexyl]pyrrolidine
Other name: TCPy;
(36) 4-Methylmethcath inone
Other names: mephedrone; methpadrone; 4-MMC;
(37) 3,4-Methylenedioxypyrovalerone
Other name: MDPV;
(38) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanam ine (2C-E);
(39) 2-(2, 5-Dimethoxy-4-methylphenyl)ethanam ine (2C-D) ;
(40) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(41) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-l);
y I i i p (42) 2-14 -Et h t h o -2, 5-d m et h oxy h e n y I I et h a n a m i n e (2C -T -2) ;
(43) 2-14-(lsopropylthio)-2, 5-dimethoxyphenyllethanam in e (ZC-T -4;
(44) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ;
(45) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ;
(46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) ;
(a7) Thiophene analogue of phencyclidine
Other names: 1-[1-(2-thienyl)cyclohexyl]piperidine; 2-thienylanalog of phencyclidine; TPCP; TCP;
(48) 3,4, s-Trimethoxyamphetamine;
(a9) (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
Other names: UR-144; 1-pentyl-3-(2,2,3,3 tetramethylcyclopropoyl)indole; or
(50) [1-(5-Fluoro-pentyl)-1H-indol-3-yll(2,2,3,3{etramethylcyclopropyl) methanone
Other names : S-fl uoro-U R - 1 44; 5-F -UR- 1 44: XLR- 1 1 1 -(5-fl uoro-pentyl)-3- (2, 2,3, 3-tetramethylcyclopropoyl)indole.
(e) Depressants, unless specifically excepted or unless listed in another schedule, means any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specified chemical designation:
8 HB 1832
(1) Etizolam
Other names: Etilaam, Etizola, Sedekopan, Pasaden, Depas;
(2) Gamma-hydroxybutyric acid
Other names: GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4- hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate;
(3) Mecloqualone; or
(4) Methaqualone.
(f) Stimulants, unless specifically excepted or unless listed in another schedule, means any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central neryous system, including its salts, isomers, and salts of isomers:
(1 ) Alpha-pyrrolidinobutiophenone
Other names: [alpha]-PBP; 1 -phenyl-2-(pyrrolidin-1 -yl)butan-1 -one;
(2) Alpha-pyrrolidinopentiophenone
Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2- (pyrrolidin-1 -yl)pentan- 1 -one;
(3) Aminorex
Other names: aminoxophen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-
phenyl-2-oxazolamine ;
(4) Butylone
Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one;
(5) Cathinone
Other names: 2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone; 2- aminopropiophenone; norphedrone; constituent of catha edulis or "Khat" plant;
(6) 3-Fluoro-N-methylcathinone
Other names: 3-FMC; 1 -(3-fluorophenyl)-2-(methylamino)propan-1 -one;
(7) 4-Fluoro-N-methylcathinone
Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1- one;
(8) Fenethylline;
(9) Methcathinone
Other names: 2-(methylamino)-propiophenone; alpha-(methylamino) propiophenone; 2-(methylamino)-1 -phenylpropan-1 -one; alpha-N- methylaminopropiophenone; monomethylpropion; ephedrone; N- methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR1 432;
(1 0) (+/-)cis4-Methylaminorex (cis isomer)
Other name: (+/-)cis-4,5 dihydro-4-methyl-5-phenyl-2-oxazolamine;
(1 1 ) 4-Methyl-N-ethylcathinone
9 HB {832
Other names: 4-M EC; 2-(ethylamino)- 1 -(4-methylphenyl)propan- 1 -one;
(1 2) 4-Methyl-alpha-pyrrolidinopropiophenone
Other names: 4-MePPP; MePPP; 4-methyl-[alpha]-pyrrolidinopropiophenone; 1- (4-methylphenyl)-2-(pyrrolidin-1 -yl)-propan- 1 -one;
(13) Naphyrone
Other names: naphthylpyrovalerone; 1-(naphth alen-2-yl)-2-(pyrrolidin-1- yl)pentan-1-one;
(1 4) N-Benzylpiperazine
Other names: BZP; 1 -benzylpiperazine;
(1 5) N-Ethylamphetamine;
(1 6) N, N-Dimethylamphetamine
Other names: N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha- trimethylphenethylam ine;
(17) Pentedrone
Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1 - phenylpentan-1 -one; or
(18) Pentylone
Other names: bk-MBDP; 1-(1 ,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one.
(g) Cannabimimetic agents, unless specifically exempted or unless listed in another schedule, means any material, compound, mixture, or preparation that contains any quantity of the following substances, or that contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP- 47,497);
(2) 5-( 1, 1 -Dimethyloctyl)-2-[(1 R, 3S)-3-hydroxycyclohexyl]-phenol
(can nabicyclohexano I or CP -47,497 G8-hom olog) ;
(3) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);
(4) 1 -Butyl-3-(1 -naphthoyl)indole (JWH-073);
(5) 1 -Hexyl-3-(1 -naphthoyl)indole (JWH-01 9);
(6) 1 -t2-(4-Morpholinyl)ethyll-3-( 1 -naphthoyl)indole (JWH-200);
(7) 1 -Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ;
(8) 1 -Pentyl-3-[1 -(4-methoxynaphthoyl)]indole (JWH-081 );
(9) 1 -Pentyl-3-(4-methyl- 1 -naphthoyl) i ndole (JWH-1 22);
(1 0) 1 -Pentyl-3-(4-chloro-1 -naphthoyl)indole (JWH-398);
(1 1 ) (1 -(5-Fluoropentyl)-1 H-indazol-3-yl)(naphthalen-1 -yl)methanone (THJ-2201);
(12) 1 -(s-Fluoropentyl)-3-(1 -naphthoyl)indole (AM2201 );
10 HB 1832
( 1 3) 1 -(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ;
(1 4) 1-Pentyl-3-[(4-methoxy)-benzoyl] i ndole (S R- 1 9 and RCS-4) ;
(1 5) 1 -Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-1 8 and RCS-8);
(1 6) 1 -Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ;
(1 7) Methyl 2-(1 -(cyclohexylmethyl)-1 h-indole-3-carboxamido)-3,3- dimethylbutanoate
Other names: MDMB-CHMICA, MMB-CHMINACA;
( 1 8) Methyl 2-(1 -(a-fluorobenzyl)- t h-i ndazole-3-carboxam ido)-3, 3- dimethylbutanoate
Other name: MDMB-FUBINACA;
( 1 9) Methyl 2-( 1 -(5-fl uoropentyl)- t h-indazole-3-carboxamido)-3- methylbutanoate
Other name: SF-AMB;
(20) Methyl 2-( 1 -(S-fl uoropentyl)- t h-indazole-3-carboxamido)-3, 3- dimethylbutanoate
Other names: SF-ADB, 5F-MDMB-PINACA;
(21 ) N-(1 -adamantyl)-1 -pentyl-1 H-indazole-3-carboxamide
Other names: APINACA; AKB48;
(22) N-(adamantan-1 -yl)-1 -(5-fluoropentyl)-1 H-indazole-3-carboxam ide
Other names: 5F-APINACA, 5F-AKB48;
(23) N-(1 -amino-3-methyl- 1 -oxobutan-2-yl)- 1 -(4-fluorobenzyl)- 1 H-
i ndazo le-3-carboxam ide
Other name: AB-FUBINACA;
(24) N-( 1 -amino-3-methyl- 1 -oxobutan-2-yl)- 1 (cyclohexylmethyl)- 1 H-
i ndazole-3-carboxam ide
Other name: AB-CHMINACA;
(25) N-(1 -am ino-3, 3-dimethyl-1 -oxobutan-2-yl)- 1 -(4-fluorobenzyl) 1 H- indazole-3-carboxam ide
Other name: ADB-FUBINACA;
(26) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H-indazole-3- carboxamide
Other name: ADB-PINACA;
(27) N-(1 -amino-3-methyl-1 -oxobutan-2-yl)- 1 -pentyl- 1 H-indazole-3- carboxamide
Other name:AB-PINACA;
(28) Quinolin-8-yl 1 -(5-fluoropentyl)-1 H-indole-3-carboxylate
Other names: S-fluoro-PB -22; 5F -PB-22; or
11 HB 1832
(29) Quinolin-8-yl 1 -pentyl-1 H-indole-3-carboxylate
Other names: PB-22; QUPIC.
SECTION 4. Tennessee Code Annotated, Section 39-17-408(c), is amended by deleting the subsection in its entirety and substituting the following:
(c) Opiates, unless specifically excepted or unless in another schedule, means any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted :
(1) Alfentanil;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) Carfentanil;
(6) Dextroproporyphene (bulk, non-dosage forms);
(7) Dihydrocodeine;
(8) Diphenoxylate;
(9) Fentanyl;
(10) lsomethadone;
(1 1 ) Levo-alphacetylmethadol
Other names: levo-alpha-acetylmethadol; levomethadyl acetate; LAAM;
(12) Levomethorphan;
(13) Levorphanol;
(14) Metazocine;
(15) Methadone;
(1 6) Methadone-l ntermediate; 4-cyano-2-dimethylamino-4,4-diphenyl butane;
( 1 7) Moramide-lntermediate; diphenylpropane-carboxylic acid ; 2-methyl- 3-morpholino-1, 1 -Pethidine (meperidine);
(1 8) Pethidine (meperidine);
( 1 9) Pethidine-l ntermediate-A; 4-cyano-1 -methyl-4-phenylpiperidine;
(20) Pethidine-lntermediate-B; ethyl-4-phenylpiperidine-4-carboxylate;
(21) Pethidine-lntermediate-C; 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(22) Phenazocine;
(23) Piminodine;
(24) Racemethorphan;
12 HB 1832
(25) Racemorphan;
(26) Remifentanil;
(27) Sufentanil;
(28) Tapentadol; or
(29) Thiafentanil.
SECTION 5. Tennessee Code Annotated, Section 39-17-408(f), is amended by deleting the subsection in its entirety and substituting the following:
(f) Hallucinogenic substances:
(1) Nabilone
Other names: (+/-)-trans-3-( 1, 1 -dimethylheptyl)-6,6a, 7, 8, 1 0, 1 ga-hexahydro- 1 - hydroxy-6,6-dimethyl-9H-dibenzoIb, d]pyran-9-one; or
(2) Dronabinol in oral solution in drug product approved for marketing by United States food and drug administration
Other names: [(-)-delta-9-trans tetrahydrocannabinol], Syndros.
SECTION 6. Tennessee Code Annotated, Section 39-17-408(gX2XA), is amended by deleting the subdivision in its entirety and substituting the following:
(A) 1 -phenylcyclohexylamine; or
SECTION 7. Tennessee Code Annotated, Section 39-17-410(fl(1), is amended by deleting the subdivision in its entirety and substituting the following:
(1) Anabolic steroids:
(A) 3[alpha], 1 7[beta]-dihydroxy-5a-androstane;
(B) 1 7[alpha]-methyl-3[alpha], 1 7[beta]-dihydroxy-Sa-androstane;
(C) 1 7[alpha]-methyl-3[beta], 1 7[beta]-dihydroxy-Sa-androstane ;
(D) 1 7[alpha]-methyl-3[beta], 1 7[beta]-dihydroxyandrost-4-ene;
(E) 1 7[alpha]-methyl-[delta] 1 -dihydrotestosterone(1 7[beta]-hydrory- 1 7[alpha]-methyl-S[alpha]-androst- 1 -en-3-one
Other Names: 1 7-[alpha]-methyl-1 testosterone;
(F) 1 7[alpha]-methyl-4-hydroxynandrolone( 1 7[alpha]-methyl-4-hydroxy-
1 7 [beta]-hyd roxyestr-4-en-3-one) ;
(G) 1 -Androstenediol (3[alpha], 1 7[beta]-dihydroxy-S[alpha]-androst-1 - ene);
(H) 1-Androstenediol (3[beta],17[beta]-dihydroxy-S[alpha]-androst-1-ene);
(l) 4-Androstenediol (3[beta], 1 7[beta]-dihydroxy-androst-4-ene) ;
(J) S-Androstenediol (3[beta], 1 7[beta]-dihydroxy-androst-5-ene);
(K) 1-Androstenedione (5[alpha]-androst-1 -en-3,1 7-dione);
(L) 4-And rostenedione (and rost-4-en-3, 1 7-dione) ;
(M) S-Androstenedione (androst-S-en-3, 1 7-dione);
13 HB 1832
(N) 3[Beta], 1 7[beta]-dihydroxy-5a-androstane;
(O) 1 3[Beta]-ethyl-1 7[beta]-hydroxygon-4-en-3-one;
(P) Androstanedione (5[alpha]-androstan-3, 1 7-dione) ;
(Q) Bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4- en-3-one);
(R) Boldenone (1 7[beta]-hydroxyandrost-1,4-diene-3-one) ;
(S) Boldione (androsta-1,4-diene-3, 1 7-dione);
(T) Calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4- en-3-one);
(U) Clostebol (4-chloro-1 7[beta]-hydroxyandrost-4-en-3-one)
Other Name: 4-Chlorotestosterone;
(V) Dehydrochloromethyltestosterone (4-chloro-1 7[beta]-hydroxy-
1 7[alpha]-methylandrost-1,4-dien-3-one) ;
(W) [Delta] 1 -d i hyd rotestosterone ( 1 7[beta]-hyd rory-S[al pha]-androst- 1 - en-3-one)
Other name: ltestosterone;
(X) Desoxymethyltestosterone ( 1 7[alpha]-methyl-5[alpha]-androst-2-en- 17[beta]-ol)
Other name: madol;
ff) a-Dihydrotestosterone (1 7[beta]-hydroxyandrostan-3-one);
(Z) Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-S[alpha]-androstan-3- one);
(AA) Ethylestrenol (1 7[alpha]-ethyl-1 7[beta]-hydroxyestr-4-ene);
(BB) Fluoxymesterone (9-fluoro-1 7[alpha]-methyl- 1 1 [beta], 1 7[beta]- d i hyd roxyand rost-4-en-3-one) ;
(CC) Formebolone (2-formyl-1 7[alpha]-methyl-1 1 [alpha], 1 7[beta]- dihydroxyandrost- 1,4-dien-3-one);
(DD) Furazabol ( 1 7[alpha]-methyl-1 7[beta]-hydroxyandrostano[2, 3-c]- furazan);
(E E) a-Hyd roxy- 1 9-nortestosterone (4, 1 7 [beta]-d i hyd roxyestr-4-en-3- one);
(FF) a-Hyd roxytestosterone (4, 1 7[beta]-di hyd roxyand rost-4-en-3-one) ;
(GG) Mestanolone ( 1 7[alpha]-methyl- 1 7[beta]-hydroxy-S[alpha]- androstan-3-one);
(HH) Mesterolone (1[alpha]-methyl-17[beta]-hydroxy-S[alpha]-androstan- 3-one);
(ll) Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1 ,4-diene- 3-one);
(JJ) Methandranone;
14 HB 1832
(KK) Methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroryandrost-S- ene);
(LL) Methandrostenolone;
(MM) Methasterone (2[alpha], 1 7[alpha]-dimethyl-S[alpha]-androstan- 17[beta]-ol-3-one);
(N N) Methenolone (1 -methyl- 1 7[beta]-hydroxy-S[alpha]-androst- 1 -en-3- one);
(OO) Methyldienolone (1 7[alpha]-methyl-1 7[beta]-hydroxyestra-4,9(1 0)- dien-3-one);
(PP) Methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en- 3-one);
(QQ) Methyltrienolone ( 1 7[alpha]-methyl- 1 7[beta]-hydroxyestra-4, 9, 1 1 - trien-3-one);
(RR) Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en- 3-one);
(SS) Nandrolone (1 7[beta]-hydroxyestr-4-en-3-one) ;
(TT) 19-Nor-4,9(10)-androstadienedione (estra4,9(10)-diene-3,17-dione);
(U 1 pha], U) 9-Nor-4-and rostened iol (3[al 1 7 [beta]-di hyd roxyestr-4-ene) ;
(W) 1 9-Nor-4-and rostened iol (3[beta], 1 7 [beta]-dihyd roxyestr-4-ene) ;
(\ /W) 19-Nor-S-androstenediol (3[alpha],17[beta]-dihydroxyestr-5-ene);
(XX) 1 9-Nor-5-and rostened iol (3[beta], 1 7[beta]-d i hydroxyestr-5-ene) ;
(W) 1 9-Nor-4-and rostened ione (estr-4-en-3, 1 7-dione) ;
(ZZ) 1 9-N or-S-a ndrostened ione (estr-5-en-3, 1 7-dione) ;
(AAA) Norbolethone (1 3[beta], 1 7[alpha]-diethyl-1 7[beta]-hydroxygon-4- en-3-one);
(BBB) Norclostebol (4-chloro-1 7[beta]-hydroxyestr-4-en-3-one);
(CCC) Norethandrolone (1 7[alpha]-ethyl-1 7[beta]-hydroxyestr-4-en-3- one);
(DDD) Normethandrolone ( 1 7[alpha]-methyl- 1 7[beta]-hydroxyestr-4-en-3- one);
(EEE) Oxandrolone (1 7[alpha]-methyl-1 7[beta]-hydroxy-2-oxa-S[alpha]- androstan-3-one);
(FFF) Oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en- 3-one);
(GGG) Oxymetholone ( 1 7[alpha]-methyl-2-hydroxymethylene- 1 7[beta]-
hydroxy-[5[alpha]l-and rostan-3-o ne) ;
(H H H) Prostanozol ( 1 7[beta]-hydroxy-S[alpha]-androstano[3, 2- clpryazole);
(l I l) Stanolone ( 1 7[beta]-hydroxy-5alpha-androstan-3-one);
15 HB 1832
(JJJ) Stanozolol (lTlalphal-methyl-17[beta]-hydroxy-[5[alpha]l-androst-2-
eno[3,2-c]-pyrazole) ;
(KKK) Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]l-androst-1-en-3- one);
(LLL) Testolactone ( 1 3-hyd roxy-3-oxo- 1 3, 1 7-secoandrosta- 1,4-dien-17 - oic acid lactone);
(M M M) Testosterone ( 1 7[beta]-hyd roxyand rost-4-en-3-one) ;
(NNN) Tetrahydrogestrinone (1 3[beta], 1 7[alpha]-diethyl-1 7[beta]- hydroxygon -4,9,1 1 trien-3-one); or
(OOO) Trenbolone (1 7[beta]-hydroryestr-4,9, 1 1 -trien-3-one).
SECTION 8. Tennessee Code Annotated, Section 39-17-412(9), is amended by deleting the subsection in its entirety and substituting the following:
(g) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts:
(1) Pentazocine;
(2) Butorphanol (including its optical isomers); or
(3) Eluxadoline (5-[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6- dimethylphenyll-1 -oxopropyll[(1 S)-1 -(4-phenyl-1 H-imid azol-2- yl)ethyllaminolmethyll-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers.
SECTION 9. Tennessee Code Annotated, Section 39-17-414(d), is amended by deleting the subsection in its entirety and substituting the following:
(d) Depressants, unless specifically exempted or excluded or unless listed in another schedule, means any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
(1) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide);
(2) Ezogabine IN-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl esterl;
(3) Gabapentin [1 -(aminomethyl)cyclohexaneacetic acid];
(4) Lacosam ide [(R)-2-acetoam ido-N-benzyl-3-methoxy-propionamide]; or
(5) Pregabalin [(S)-3-(aminomethyl)-5-methylhexonoic acid].
SECTION 10. Tennessee Code Annotated, Section 39-17-452(a), is amended by adding the following as a new subdivision (a)(3):
(A) lt is an offense for a person to knowingly:
(i) Sell, or offer for sale, Kratom unless labeled and in its natural form;
(ii) Distribute, sell, or offer for sale, Kratom to a person under the age of twenty-one (21) years; or
(iii) Purchase or possess Kratom if under the age of twenty-one (21) years.
(B) For purposes of this subdivision (a)(3):
16 HB 1832
(i) "Labeled" means a label containing the manufacturer's information and a warning that includes, at a minimum, 'Warning: Do not use if you are pregnant or nursing. lt is illegal to possess Kratom if under 21 years of age. Consult your healthcare professional before using. Do not combine with alcohol or medication. Consult a doctor prior to usage if you have any heart disease, liver disorder, high blood pressure, or medical condition or take medication."; and
(ii) "Natural form" means dried, cut, and sifted Kratom leaf or raw Kratom leaf powder.
SECTION 11 Tennessee Code Annotated, Section 41-21-236(a)(2), is amended by redesignating subdivision (a)(2)(D) as subdivision (aX2XBXiv), adding the following as a new subdivision (a)(2)(C), and redesignating the existing subdivisions accordingly: (c)
(i) ln addition to the credits authorized by subdivisions (aX2XA) and (B), the department shall provide a credit of sixty (60) days to any qualifying prisoner who successfully completes an evidence-based, intensive residential substance use disorder treatment therapeutic community program of at least nine (9) months in the department.
(ii) lt is the legislative intent that this credit be implemented by the department in a manner that maximizes the potential of prisoners who have a history of substance use disorders returning to the community to become working and productive members of society by breaking the cycle of substance use and criminal behavior through successful completion of intensive substance use disorder treatment.
(iii) The provisions of this subdivision (aX2XC) permitting an additional sixty (60) days of credit for successful completion of the intensive substance use disorder treatment program shall not apply to any prisoner convicted of an offense that requires service of at least eighty-five percent (85%) of the sentence under S 40-35-501(i) or one hundred percent (100o/o) of the sentence under $ 39- 13-s23 or $ 40-35-501(l).
(iv) The sixty (60) days of credit authorized by this subdivision (aX2XC) shall apply to any inmate who successfully completes an evidence-based, intensive residential substance use disorder treatment therapeutic community program of at least nine (9) months in the department on or after July 1,2018.
SECTION 12. lf any provision of this act or the application of any provision of this act to any person or circumstance is held invalid, the invalidity does not affect other provisions or applications of the act that can be given effect without the invalid provision or application, and to that end, the provisions of this act are declared to be severable.
SECTION 13. This act shall take effect July 1 ,2018, the public welfare requiring it.
17 HOUSE BILL NO. 1832
PASSED: April 25.2018
p n rA BETH HARWELL, SPEAKER HOUSE OF REPRESENTATIVES
RANDY MCNALLY SPEAKER OF THE SENATE
APPRovED this 2tnJ day of 2018
t
BILL , GOVERNOR